Core Insights - Lottery.com Inc. and Sports.com-backed drivers showcased strong performances at Road America during a challenging weekend of the NTT INDYCAR SERIES and INDY NXT by Firestone [1][2] Group 1: Performance Highlights - Louis Foster, driving Car No. 45 for Rahal Letterman Lanigan, achieved a remarkable pole position, outperforming established competitors despite using older tires [5][6] - Callum Ilott, in Car No. 90 for PREMA Racing, secured his best finish of the 2025 season with a P15 result, demonstrating effective tire strategy and pit work [8][9] - Sebastian Murray, driving Car No. 2 for Dream Racing Dubai Dallara in INDY NXT, moved from P14 to P11, earning the title of Jostens' Biggest Mover of the day [11][12] Group 2: Company Statements and Future Plans - Matthew McGahan, CEO of Lottery.com and Sports.com, expressed pride in the partnership with the young drivers, emphasizing a strategic selection process aimed at long-term investment in future champions [12][14] - The company noted a significant increase in brand exposure and interest from other IndyCar teams and global motorsport series, indicating positive momentum [13][15] - Plans are underway to develop a comprehensive driver and team development and sponsorship program for 2026, with the current drivers positioned as key components of this initiative [14][15]

Key Takeaways TJX delivered 3% comparable sales growth in Q1, driven entirely by higher customer traffic. All four segments, led by HomeGoods and international units, contributed to the sales gain. Management guided for 2-3% comparable sales growth in the second quarter of fiscal 2026.The TJX Companies, Inc. (TJX) delivered comparable store sales growth of 3% in the first quarter of fiscal 2026, with all four major divisions contributing to the gain. The growth was entirely driven by increased customer tr ...

点击下方 卡片 ，关注" 自动驾驶之心 "公众号 戳我-> 领取 自动驾驶近15个 方向 学习 路线 今天自动驾驶之心为大家分享 北理工&清华 最新的工作！ MMTL-UniAD：辅助 驾驶感知中多模态和多任务学习的统一框架（CVPR'25）。 如果您有相关工作需 要分享，请在文末联系我们！ 自动驾驶课程学习与技术交流群事宜，也欢迎添加小助理微信AIDriver004做进一 步咨询 >>点击进入→ 自动驾驶之心 『多任务学习』技术交流群 论文作者 | Wenzhuo Liu等 高级驾驶辅助系统需要对驾驶员的心理/生理状态以及交通环境进行全面感知，但现有研究往往忽视了这 些任务之间联合学习所带来的潜在优势。本文提出了一种统一的多模态多任务学习框架——MMTL- UniAD，该框架可同时识别驾驶员行为（如四处张望、交谈）、驾驶员情绪（如焦虑、愉快）、车辆行 为（如变道、转向）以及交通环境（如拥堵、通畅）。本研究的关键挑战在于如何缓解多任务联合学习 过程中产生的负迁移现象。该现象是多任务学习中核心难点，指由于任务间存在差异或冲突，导致某些 任务在联合训练下的性能反而低于其单独训练时的表现。为解决这一问题，我们在框架 ...

Driverless Robotaxi drive at night. It’s insane to see Teslas without drivers.We are living in the future. https://t.co/iozHvMfg2C ...

RT Tesla Owners Silicon Valley (@teslaownersSV)Can’t believe Tesla released the driverless Robotaxi today. It’s absolutely insane and takes us closer to a fully autonomous future. https://t.co/d8pIFEdbwq ...

RT Tesla Owners Silicon Valley (@teslaownersSV)Stepping into a driverless Tesla Robotaxi https://t.co/k5ABLAA7QT ...

Stepping into a driverless Tesla Robotaxi https://t.co/k5ABLAA7QT ...

RT Tesla Owners Silicon Valley (@teslaownersSV)Seeing driverless Cars will become a normal thing.🤖🚖 are here @anuarbekiman https://t.co/xy5I7gBRmi ...

Seeing driverless Cars will become a normal thing.🤖🚖 are here @anuarbekiman https://t.co/xy5I7gBRmi ...

Core Insights - Sanofi and Regeneron received FDA approval for Dupixent to treat bullous pemphigoid, marking it as the first targeted therapy for this condition in the U.S. [1][7] - Dupixent is now approved for eight type II inflammatory diseases in the U.S. [1] Group 1: Dupixent Approval and Indications - Dupixent is approved for treating bullous pemphigoid, a chronic skin disease affecting approximately 27,000 adults in the U.S. [2] - The drug has prior approvals for several conditions, including severe asthma and chronic rhinosinusitis [2][6] - The latest approval is based on phase II/III ADEPT study data showing significant improvements in disease remission and reduced corticosteroid use [6][8] Group 2: Market Performance and Sales - In Q1 2025, Dupixent generated global sales of €3.48 billion, reflecting a 20.3% growth at constant exchange rates [10] - Sanofi anticipates Dupixent will reach around €22 billion in sales by 2030 [10] - Regeneron reported collaboration revenues of $1.18 billion from Sanofi in Q1 2025, a 30% year-over-year increase [10] Group 3: Future Prospects and Regulatory Applications - Regulatory applications for Dupixent in bullous pemphigoid are under review in the EU, Japan, and China [8] - The expanding label of Dupixent reinforces its role in managing type II inflammation-driven diseases, potentially shifting standard-of-care practices [7][8]